NCT01016093Unknown2 期
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients: A Prospective Pilot Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- To describe the percent change in the lumbar spine (L1 to L4) BMD, as measured by dual energy X-ray absorptiometry, at 12 months in patients with beta-thalassemia major undergoing allogenic BMT randomized to zoledronic acid versus placebo.
研究概览
简要总结
This is prospective randomized, double blind study designed to evaluate the use of zoledronic acid in the prevention prevention of bone loss post allogenic BMT done for beta-thalassemia major patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent.
- •Patients must be 18 years old and over.
- •Diagnosed with beta-thalassemia major
- •Scheduled for allogenic bone marrow transplantation
- •The date of randomization must be no more than 1 week after BMT.
- •Patients must be accessible for follow-up.
- •Life expectancy of at least 12 months from randomization.
排除标准
- •Patients with any clinical or radiological evidence of existing fracture in the lumbar spine and/or total hip.
- •Patients with a history of fracture with low-density or no associated trauma.
- •Osteoporotic patients with T-score <= -2.5
- •Previous treatment with a bisphosphonate.
- •Patients with abnormal renal function as evidenced by either a serum creatinine determination 1.5 x or greater above the upper limit of normal or by a calculated creatinine clearance of 30 ml/minute or less.
- •Pregnancy and lactation.
- •Women of childbearing potential not on a medically recognized form of contraception.
- •Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study.
- •Subjects participating simultaneously in studies with unapproved drugs, indications or treatment regimens.
- •Known hypersensitivity to zoledronic acid or bisphosphonates.
- •Patients with prior exposure to anabolic steroids, growth hormone, Parathyroid Hormone (PTH) or other drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate).
- •Serious intercurrent illness
- •History of metabolic bone diseases
- •History of corticosteroid treatment for other causes
- •History of antiepileptic drug treatment
- •History or surgery at the lumbosacral spine, with or without implantable devices.
- •Any disease of the spine that would preclude the proper acquisition of a lumbar spine DXA.
- •Mental illness that precludes the patient from giving informed consent.
- •Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- •Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)
研究组 & 干预措施
Intervention
Experimental
Patients in this arm received zoledronic acid.
干预措施: Zoledronic acid (Drug)
Control
Placebo Comparator
Patients in this arm received placebo as control group
干预措施: Placebo (Drug)
结局指标
主要结局
To describe the percent change in the lumbar spine (L1 to L4) BMD, as measured by dual energy X-ray absorptiometry, at 12 months in patients with beta-thalassemia major undergoing allogenic BMT randomized to zoledronic acid versus placebo.
时间窗: 1 year
次要结局
- To describe the percent change in total hip BMD at 12 months in the two study arms.(1 year)
- To compare the changes in bone turn over markers at 3, 6, and 12 months in the two treatment arms.(1 year)
- To describe the incidence rate of all clinical fractures at 1 year in the two study arms.(1 year)
- To describe the general safety of zoledronic acid.(1 year)
- To describe the percent change in lumbar spine (L1 to L4) BMD and total hip BMD at 6 months when available.(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)Bone LossMuscle AtrophyBariatric SurgeryNCT04742010Stinus Gadegaard Hansen59
已完成
3 期
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple MyelomaTreatment of Bone MetastasesNCT00219258Novartis240
已完成
2 期
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal SymptomsDuctal Carcinoma in SituEstrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerStage I Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerNCT01194440Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins63
招募中
2 期
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill AdultsCritical IllnessOsteoporosisNCT04608630Australian and New Zealand Intensive Care Research Centre450
已完成
2 期
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate CancerBone LossProstate CancerNCT00181584Massachusetts General Hospital60